- Home
- LGI vs CDXS Comparison
LGI vs CDXS Comparison
Compare LGI & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGI
- CDXS
- Stock Information
- Founded
- LGI 2004
- CDXS 2002
- Country
- LGI United States
- CDXS United States
- Employees
- LGI N/A
- CDXS N/A
- Industry
- LGI
- CDXS Major Chemicals
- Sector
- LGI
- CDXS Industrials
- Exchange
- LGI Nasdaq
- CDXS Nasdaq
- Market Cap
- LGI 224.1M
- CDXS 216.6M
- IPO Year
- LGI N/A
- CDXS 2010
- Fundamental
- Price
- LGI $17.67
- CDXS $2.59
- Analyst Decision
- LGI
- CDXS Buy
- Analyst Count
- LGI 0
- CDXS 2
- Target Price
- LGI N/A
- CDXS $11.00
- AVG Volume (30 Days)
- LGI 41.1K
- CDXS 549.5K
- Earning Date
- LGI 01-01-0001
- CDXS 11-06-2025
- Dividend Yield
- LGI 7.10%
- CDXS N/A
- EPS Growth
- LGI N/A
- CDXS N/A
- EPS
- LGI N/A
- CDXS N/A
- Revenue
- LGI N/A
- CDXS $57,164,000.00
- Revenue This Year
- LGI N/A
- CDXS $12.88
- Revenue Next Year
- LGI N/A
- CDXS $21.64
- P/E Ratio
- LGI N/A
- CDXS N/A
- Revenue Growth
- LGI N/A
- CDXS N/A
- 52 Week Low
- LGI $12.66
- CDXS $1.90
- 52 Week High
- LGI $16.68
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- LGI 57.99
- CDXS 49.46
- Support Level
- LGI $17.34
- CDXS $2.52
- Resistance Level
- LGI $17.70
- CDXS $2.80
- Average True Range (ATR)
- LGI 0.28
- CDXS 0.16
- MACD
- LGI 0.05
- CDXS -0.00
- Stochastic Oscillator
- LGI 93.00
- CDXS 28.43
About LGI Lazard Global Total Return and Income Fund
Lazard Global Total Return & Inc Fd Inc is a United States-based diversified, closed-end management investment company. Its investment objective is total return consisting of capital appreciation and income. The fund's portfolio of investments consists of different sector investments such as consumer staples, financials, consumer discretionary, healthcare, materials, sovereign debt and others.
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.